Nonprofit buys experimental cancer drug to maintain patient access
In a rare move, nonprofit organization Blood Cancer United announced Thursday it was buying the remaining supplies of Luvelta, a discontinued investigational cancer drug. San Francisco-based Sutro Biopharma, which was developing Luvelta, decided to discontinue development in March 2025, to prioritize funding other drugs. And along with that, the compassionate-use program was eliminated.
- ▪In a rare move, nonprofit organization Blood Cancer United announced Thursday it was buying the remaining supplies of Luvelta, a discontinued investigational cancer drug.
- ▪San Francisco-based Sutro Biopharma, which was developing Luvelta, decided to discontinue development in March 2025, to prioritize funding other drugs.
- ▪And along with that, the compassionate-use program was eliminated.
STAT News files mainly under health. We currently carry 209 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | STAT |
| Canonical URL | https://www.statnews.com/2026/06/11/blood-cancer-united-buys-luvelta-compassionate-use/?utm_campaign=rss |
| Publication time | Thu, 11 Jun 2026 18:33:52 +0000 |
| Retrieval time | 2026-06-11T18:35:06.002Z |
| Last seen | 2026-06-11T18:35:06.002Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | VcGlwasxn6fG |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Health Nonprofit buys experimental cancer drug to maintain patient access Blood Cancer United is buying remaining supplies of Luvelta, and will manage a compassionate-use program Manage alerts for this article Email this article Share this article Adobe By Lauren ChanJune 11, 2026 AAAS Mass Media Science & Engineering Fellow Lauren Chan[email protected]Lauren writes about healthcare AI data interoperability, the science behind public health recommendations, and pharmaceutical advances in the rare disease space. In a rare move, nonprofit organization Blood Cancer United announced Thursday it was buying the remaining supplies of Luvelta, a discontinued investigational cancer drug.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT.
Discussion
0 commentsMore from STAT
